Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Impact of early cART in the gut during acute HIV infection.

Deleage C, Schuetz A, Alvord WG, Johnston L, Hao XP, Morcock DR, Rerknimitr R, Fletcher JL, Puttamaswin S, Phanuphak N, Dewar R, McCune JM, Sereti I, Robb M, Kim JH, Schacker TW, Hunt P, Lifson JD, Ananworanich J, Estes JD.

JCI Insight. 2016 Jul 7;1(10). pii: e87065.

2.

Evaluation of the FACSPresto, a New Point of Care Device for the Enumeration of CD4% and Absolute CD4+ T Cell Counts in HIV Infection.

Makadzange AT, Bogezi C, Boyd K, Gumbo A, Mukura D, Matubu A, Ndhlovu CE.

PLoS One. 2016 Jul 7;11(7):e0157546. doi: 10.1371/journal.pone.0157546. eCollection 2016.

3.

Role of Biosensing Technology for NeuroAIDS Management.

Jayant RD, Nair M.

J Biosens Bioelectron. 2016 Mar;7(1). pii: e141. Epub 2016 Feb 29. No abstract available.

4.

A Brief Chronicle of CD4 as a Biomarker for HIV/AIDS: A Tribute to the Memory of John L. Fahey.

Kagan JM, Sanchez AM, Landay A, Denny TN.

For Immunopathol Dis Therap. 2015;6(1-2):55-64.

5.

Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection.

Thornhill J, Inshaw J, Kaleebu P, Cooper D, Ramjee G, Schechter M, Tambussi G, Fox J, Samuel M, Miro JM, Weber J, Porter K, Fidler S.

J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):69-73. doi: 10.1097/QAI.0000000000001013.

6.

Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS.

Nair M, Jayant RD, Kaushik A, Sagar V.

Adv Drug Deliv Rev. 2016 Aug 1;103:202-17. doi: 10.1016/j.addr.2016.02.008. Epub 2016 Mar 2. Review.

PMID:
26944096
7.

Plasma Levels of Neopterin and C-Reactive Protein (CRP) in Tuberculosis (TB) with and without HIV Coinfection in Relation to CD4 Cell Count.

Skogmar S, Schön T, Balcha TT, Sturegård E, Jansson M, Björkman P.

PLoS One. 2015 Dec 2;10(12):e0144292. doi: 10.1371/journal.pone.0144292. eCollection 2015.

8.

Continuous Antigenic Stimulation of DO11.10 TCR Transgenic Mice in the Presence or Absence of IL-1β: Possible Implications for Mechanisms of T Cell Depletion in HIV Disease.

Ladell K, Hazenberg MD, Fitch M, Emson C, McEvoy-Hein Asgarian BK, Mold JE, Miller C, Busch R, Price DA, Hellerstein MK, McCune JM.

J Immunol. 2015 Nov 1;195(9):4096-105. doi: 10.4049/jimmunol.1500799. Epub 2015 Sep 28.

9.

Fast sorting of CD4+ T cells from whole blood using glass microbubbles.

Hsu CH, Chen C, Irimia D, Toner M.

Technology (Singap World Sci). 2015 Mar;3(1):38-44.

10.

CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients.

Lu W, Mehraj V, Vyboh K, Cao W, Li T, Routy JP.

J Int AIDS Soc. 2015 Jun 29;18:20052. doi: 10.7448/IAS.18.1.20052. eCollection 2015.

11.

Understanding frailty, aging, and inflammation in HIV infection.

Leng SX, Margolick JB.

Curr HIV/AIDS Rep. 2015 Mar;12(1):25-32. doi: 10.1007/s11904-014-0247-3. Review.

12.

Quantification of cells with specific phenotypes I: determination of CD4+ cell count per microliter in reconstituted lyophilized human PBMC prelabeled with anti-CD4 FITC antibody.

Stebbings R, Wang L, Sutherland J, Kammel M, Gaigalas AK, John M, Roemer B, Kuhne M, Schneider RJ, Braun M, Engel A, Dikshit DK, Abbasi F, Marti GE, Sassi MP, Revel L, Kim SK, Baradez MO, Lekishvili T, Marshall D, Whitby L, Jing W, Ost V, Vonsky M, Neukammer J.

Cytometry A. 2015 Mar;87(3):244-53. doi: 10.1002/cyto.a.22614. Epub 2015 Feb 5.

13.

A young man with chronic cough.

Loh K.

Malays Fam Physician. 2007 Aug 31;2(2):86. eCollection 2007. Review. No abstract available.

14.

Mode of delivery and postpartum HIV-1 disease progression and mortality in a Kenyan cohort.

Unger JA, Richardson BA, Otieno PA, Farquhar C, Wamalwa D, John-Stewart GC.

BMC Pregnancy Childbirth. 2014 Aug 3;14:257. doi: 10.1186/1471-2393-14-257.

15.

Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.

Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, Plants J, Seth A, Wilson CC, Deeks SG, Lederman MM, Landay AL.

J Infect Dis. 2014 Oct 15;210(8):1248-59. doi: 10.1093/infdis/jiu254. Epub 2014 May 1.

16.

Can early therapy reduce inflammation?

Sandler NG, Sereti I.

Curr Opin HIV AIDS. 2014 Jan;9(1):72-9. doi: 10.1097/COH.0000000000000020. Review.

17.

Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy.

Leung V, Gillis J, Raboud J, Cooper C, Hogg RS, Loutfy MR, Machouf N, Montaner JS, Rourke SB, Tsoukas C, Klein MB; CANOC Collaboration.

PLoS One. 2013 Oct 30;8(10):e77665. doi: 10.1371/journal.pone.0077665. eCollection 2013.

18.

Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection.

Pérez-Santiago J, Gianella S, Massanella M, Spina CA, Karris MY, Var SR, Patel D, Jordan PS, Young JA, Little SJ, Richman DD, Smith DM.

AIDS. 2013 Jul 31;27(12):1921-31.

19.

Immune activation and collateral damage in AIDS pathogenesis.

Miedema F, Hazenberg MD, Tesselaar K, van Baarle D, de Boer RJ, Borghans JA.

Front Immunol. 2013 Sep 26;4:298. doi: 10.3389/fimmu.2013.00298. Review.

20.

Acute HIV-1 seroconversion with an unusual plasma biomarker profile.

Aziz N, Detels R, Martinez-Maza O, Oishi J, Jamieson BD, Witt MD, Butch AW.

Clin Vaccine Immunol. 2013 Nov;20(11):1774-7. doi: 10.1128/CVI.00366-13. Epub 2013 Sep 4.

Items per page

Supplemental Content

Write to the Help Desk